Moleculin reports Q3 2022 net loss of $22.3M for nine months; cash $50.4M sufficient beyond mid-2024

Moleculin Biotech, Inc.

R&D expense $14.8M (nine months) vs $11.2M YoY; net loss $22.3M vs $13.1M.
Cash $50.4M, sufficient beyond mid-2024; operating cash burn $20.4M.
Three Phase 1/2 trials for Annamycin active; no cardiotoxicity in 42 subjects.
WP1066 pediatric brain tumor trial enrolled final subject in Phase 1 at 8 mg/kg.
WP1122 received FDA Orphan Drug for GBM; Phase 1a completed; WP1096 selected for NIH studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-026900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.